Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia;Anagrelide-induzierte veränderungen der megakaryopoiese bei der therapie thrombozythämischer chronischer myeloproliferativer erkrankungen

Pathologe

Volumn 23, Issue 6, 2002, Pages 426-432

  Thiele, J ^a   Kvasnicka, H ^a   Schmitt Graff A ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anagrelide; Bone marrow biopsies; Chronic idiopathic myelofibrosis; Endomitotic reduplication; Essential thrombocythemia; Megakaryocytes; Proliferation; Thrombocythemias

Indexed keywords

ANAGRELIDE; CD61 ANTIGEN; CYCLINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CELL MATURATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEGAKARYOBLAST; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MORPHOMETRICS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

BLOOD PLATELETS; CHRONIC DISEASE; FIBRINOLYTIC AGENTS; HUMANS; MEGAKARYOCYTES; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PROLIFERATING CELL NUCLEAR ANTIGEN; QUINAZOLINES; REFERENCE VALUES; RETROSPECTIVE STUDIES; THROMBOCYTOSIS; THROMBOPOIESIS;

EID: 0036938474     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-002-0584-7     Document Type: Article

References (48)

1. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92:69-76
2. Balduini CL, Bertolino G, Noris P, Ascari E (1992) Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 77:40-43
3. Bellucci S, Legrand C, Boval B, Drouet L, Caen J (1999) Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide. Br J Haematol 104:886-892
4. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H (1995) Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Pathol 146:1302-1308
5. Budke H, Orazi A, Neiman RS, Cattoretti G, John K, Barberis M (1994) Assessment of cell proliferation in paraffin sections of normal bone marrow by the monoclonal antibodies Ki-67 and PCNA. Mod Pathol 7:860-866
6. Dervan PA, Magee HM, Buckley C,Carney DN (1992) Proliferating cell nuclear antigen counts in formalinfixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 97:S21-28
7. Finazzi G, Barbui T (1999) Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 78:389-392
8. Furgerson JL, Vukelja SJ, Baker WJ, O'Rourke TJ (1996) Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol 51:137-140
9. Gatter KC, Cordell JL, Turley H, Heryet A, Kieffer N, Anstee DJ, Mason DY (1988) The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens. Histopathology 13:257-267
10. Gilbert HS (2002) Other secondary sequelae of treatments for myeloproliferative disorders. Semin Oncol 29:22-27
11. Hall PA, Levison DA (1990) Review: assessment of cell proliferation in histological material. J Clin Pathol 43:184-192
12. Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H (1995) Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer 75:471-477
13. Jamshidi K, Swaim WR (1971) Bone marrow biopsy with unaltered architecture: a new biopsy device. J Lab Clin Med 77:335-342
14. Kreipe H, Heidebrecht HJ, Hansen S et al. (1993) A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 142:3-9
15. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC (2000) Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 6:157-161
16. Le Bousse-Kerdiles MC, Martyre MC (1999) Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin Immunopathol 21:491-508
17. Levine RF, Hazzard KC, Lamberg JD (1982) The significance of megakaryocyte size. Blood 60:1122-1131
18. Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Fermeaux V, Praloran V, Bordessoule D (1997) Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 39:11-18
19. Mazur EM, Rosmarin AG,Sohl PA, Newton JL, Narendran A (1992) Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 79:1931-1937
20. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F (1992) Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 77:315-317
21. McCormick D,Hall PA (1992)The complexities of proliferating cell nuclear antigen. Histopathology 21:591-594
22. McCormick D, Yu C, Hobbs C, Hall PA (1993) The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology 22:543-547
23. Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39
24. Oertel MD (1998) Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm 55:1979-1986
25. Petrides PE, Beykirch MK, Trapp OM (1998) Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 61:71-76
26. Queisser U, Queisser W, Spiertz B (1971) Polyploidization of megakaryocytes in normal humans, in patients with idiopathic thrombocytopenia and with pernicious anaemia. Br J Haematol 20:489-501
27. Randi ML, Fabris F, Girolami A (2000) Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma 37:379-385
28. Ravandi-Kashani F, Schafer AI(1997) Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives. Semin Thromb Hemost 23:479-488
29. Schaefer HE (1995) Die histologische Bearbeitungstechnik von Beckenkammbiopsien auf der Basis von Entkalkung und Paraffineinbettung unter Berücksichtigung osteologischer und hämatologischer Fragestellungen. Pathologe 16:11-27
30. Silverstein MN, Petitt RM, Sotberg LA, Fleming JS, Knight RC, Schacter LP (1988) Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 318:1292-1294
31. Silverstein MN, Tefferi A (1999) Treatment of essential thrombocythemia with anagrelide. Semin Hematol 36:23-25
32. Solberg Jr. Tefferi A, Oles KJ,Tarach JS, Petitt RM, Forstrom LA, Silverstein MN (1997) The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 99:174-180
33. Solberg LA Jr (2002) Therapeutic options for essential thrombocythemia and polycythemia vera. Semin Oncol 29:10-15
34. Sterkers Y, Preudhomme C, Lai JL et al. (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91:616-622
35. Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863-866
36. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 23:379-383
37. Thiele J, Wagner S, Degel C et al. (1990) Megakaryocyte precursors (pro- and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. An immunomorphometric study. Virchows Arch B Cell Pathol Incl Mol Pathol 58:295-302
38. Thiele J, Wagner S, Dienemann D, Wienhold S, Fischer R, Stein H (1990) Megakaryocyte precursors (promegakaryoblasts and megakaryoblasts) in the normal human bone marrow. An immunohistochemical and morphometric study on routinely processed trephine biopsies. Anal Quant Cytol Histol 12:285-289
39. Thiele J, Fischer R (1991) Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview. Virchows Arch A Pathol Anat Histopathol 418:87-97
40. Thiele J, Meuter RB, Titius RB, Zankovich R, Fischer R (1993) Proliferating cell nuclear antigen expression by erythroid precursors in normal bone marrow, in reactive lesions and in polycythaemia rubra vera. Histopathology 22:429-435
41. Thiele J, Bertsch HP, Kracht LW, Anwander T, Zimmer JD, Kreipe H, Fischer R (1994) Ki-51 and PCNA expression in erythroid precursors and megakaryocytes - a comparative study on proliferative and endoreduplicative activity in reactive and neoplastic bone marrow lesions. J Pathol 173:5-12
42. Thiele J, Titius BR, Kvasnicka HM, Bertsch HP, Erdmann S, Fischer R (1994) Proliferating cell nuclear antigen (PCNA) expression of megakaryocytopoiesis in normal human bone marrow and reactive lesions with special emphasis on HIV-myelopathy. Pathol Res Pract 190:42-50
43. Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G (2001) Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) WHO Classification of tumours: tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 35-38
44. Tomer A, Friese P, Conklin R, Bales W, Archer L, Harker LA, Burstein SA (1989) Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts. Blood 74:594-601
45. Tomer A (2002) Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 99:1602-1609
46. Trapp OM, Beykirch MK, Petrides PE (1998) Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis 24:9-13
47. Williams N, Levine RF (1982) The origin, development and regulation of megakaryocytes. Br J Haematol 52:173-180
48. Yoon SY, Li CY, Mesa RA,Tefferi A (1999) Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 106:682-688